An innate tumor resistance to epidermal growth factor receptor (EGFR) small molecule inhibitors was found in 10% of non-small cell and lung carcinoma patients and the Cripto expression was higher in the cases exhibiting resistance compared to therapy responders [97,98]. The gene discussed is EGFR; the disease is neoplasm.